A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT06628362
StatusCompleted
PhasePhase 2
SponsorCarmot Therapeutics, Inc.
Enrollment447 participants
DesignInterventional, Randomized, Parallel, Masking: Double
ConditionsOverweight or Obese; Type 2 Diabetes Mellitus (T2DM)
InterventionsPlacebo; Enicepatide
StartNov 21, 2024
Primary completionMay 29, 2026
Study completionOct 2, 2026
Results postedNot yet
Registry last updatedOct 28, 2026
CollaboratorsHoffmann-La Roche

Compounds on this site that cite this trial

What the registry says the trial is about

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Percent Change in Body Weight from Baseline to Week 36Baseline to Week 36
Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36Baseline to Week 36

24 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail